Research Analysts Offer Predictions for CGEM Q1 Earnings

Key Points

• HC Wainwright predicts Cullinan Therapeutics will report Q1 2026 earnings of ($1.05) per share, maintaining a "Buy" rating and a price target of $24.00.
• Recent earnings revealed a loss of ($1.07) per share, missing estimates of ($0.83) and underscoring the company's challenges in financial performance.
• Institutional investors have significantly increased their stakes in Cullinan Therapeutics, with major increases from firms like JPMorgan Chase and GAMMA Investing.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Cullinan Therapeutics in a research report issued to clients and investors on Thursday, August 21st. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($1.05) per share for the quarter. HC Wainwright has a "Buy" rating and a $24.00 price objective on the stock. The consensus estimate for Cullinan Therapeutics' current full-year earnings is ($3.04) per share. HC Wainwright also issued estimates for Cullinan Therapeutics' Q2 2026 earnings at ($1.08) EPS.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.24).

Several other brokerages have also recently commented on CGEM. Stifel Nicolaus assumed coverage on Cullinan Therapeutics in a research report on Wednesday, June 11th. They issued a "buy" rating and a $22.00 target price for the company. Morgan Stanley cut their price objective on Cullinan Therapeutics from $35.00 to $28.00 and set an "overweight" rating for the company in a report on Monday. Finally, UBS Group cut their price objective on Cullinan Therapeutics from $30.00 to $24.00 and set a "buy" rating for the company in a report on Monday, May 12th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $26.80.

Cullinan Therapeutics Stock Up 2.7%

Shares of Cullinan Therapeutics stock opened at $7.67 on Friday. The stock has a market cap of $453.07 million, a PE ratio of -2.37 and a beta of -0.08. The business has a fifty day simple moving average of $7.80 and a 200-day simple moving average of $8.20. Cullinan Therapeutics has a 12 month low of $6.85 and a 12 month high of $19.89.

Institutional Trading of Cullinan Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its stake in Cullinan Therapeutics by 580.9% in the fourth quarter. JPMorgan Chase & Co. now owns 198,214 shares of the company's stock valued at $2,414,000 after acquiring an additional 169,104 shares during the period. GAMMA Investing LLC increased its stake in Cullinan Therapeutics by 1,214.8% in the first quarter. GAMMA Investing LLC now owns 6,995 shares of the company's stock valued at $53,000 after acquiring an additional 6,463 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Cullinan Therapeutics by 29.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 91,792 shares of the company's stock valued at $1,118,000 after acquiring an additional 20,881 shares during the period. Rhumbline Advisers increased its stake in Cullinan Therapeutics by 4.6% in the first quarter. Rhumbline Advisers now owns 71,338 shares of the company's stock valued at $540,000 after acquiring an additional 3,130 shares during the period. Finally, Invesco Ltd. increased its stake in Cullinan Therapeutics by 2.4% in the fourth quarter. Invesco Ltd. now owns 59,553 shares of the company's stock valued at $725,000 after acquiring an additional 1,395 shares during the period. Institutional investors own 86.31% of the company's stock.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.